Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-Hour Exclusions and Association With Outcome Data From Get With The Guidelines-Stroke

被引:33
作者
Cronin, Carolyn A. [1 ]
Sheth, Kevin N. [2 ]
Zhao, Xin [3 ]
Messe, Steven R. [4 ]
Olson, DaiWai M. [5 ]
Hernandez, Adrian F. [3 ]
Bhatt, Deepak L. [6 ,7 ]
Schwamm, Lee H. [7 ,8 ]
Smith, Eric E. [9 ,10 ]
机构
[1] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA
[2] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA
[3] Duke Clin Res Inst, Durham, NC USA
[4] Hosp Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA
[5] Univ Texas Southwestern, Dept Neurol, Dallas, TX USA
[6] Brigham & Womens Hosp, Dept Cardiol, Boston, MA 02115 USA
[7] Harvard Univ, Sch Med, Boston, MA USA
[8] Massachusetts Gen Hosp, Dept Neurol, Inst Heart Vasc & Stroke Care, Boston, MA 02114 USA
[9] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada
[10] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada
关键词
stroke; thrombolytic therapy; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; THROMBOLYSIS; ALTEPLASE; ATTACK; TRIAL; OLDER; TIME;
D O I
10.1161/STROKEAHA.114.005443
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-The American Heart Association/American Stroke Association guidelines recommend intravenous tissue-type plasminogen activator (tPA) treatment 3 to 4.5 hours from symptom onset according to criteria used in the Third European Cooperative Acute Stroke Study (ECASS III). However, ECASS III excluded certain patient groups in addition to the standard exclusions used for 0 to 3 hours in the United States: age > 80 years, history of stroke and diabetes mellitus, oral anticoagulant treatment, and National Institutes of Health Stroke Scale > 25. We investigated adherence to these additional exclusion criteria for patients treated 3 to 4.5 hours from onset and their association with outcome. Methods-We analyzed data from Get With The Guidelines-Stroke on 32 019 patients with ischemic stroke from 1464 hospitals who were treated with tPA <= 4.5 hours from onset from January 2009 to January 2012, excluding patients transferred from another hospital. The percent of patients meeting versus not meeting each exclusion criterion were compared between treatment time windows. Results-Overall, 1544 of 4910 (31.5%) patients treated with tPA > 3 to 4.5 hours had at least 1 of the additional exclusions, the most common was age > 80 years. With the exception of prior stroke and diabetes mellitus, the percent of tPA-treated patients with each exclusion criterion was significantly lower at > 3 to 4.5 hours compared with 0 to 3 hours. For each additional exclusion criterion, there was no increased risk of symptomatic intracranial hemorrhage or worse hospital outcome for patients treated > 3 to 4.5 hours compared with 0 to 3 hours, after adjusting for baseline differences. Conclusions-Patients with ECASS III-specific exclusion criteria for the > 3 to 4.5 hours window are frequently treated with tPA. The presence of the additional exclusion criteria was not associated with worse outcomes in the > 3 to 4.5 hours window compared with the 0 to 3 hours window.
引用
收藏
页码:2745 / +
页数:7
相关论文
共 19 条
[1]   Is Thrombolysis Safe in the Elderly? Analysis of a National Database [J].
Alshekhlee, Amer ;
Mohammadi, Afshin ;
Mehta, Sonal ;
Edgell, Randall C. ;
Vora, Nirav ;
Feen, Eli ;
Kale, Sushant ;
Shakir, Zaid A. ;
Cruz-Flores, Salvador .
STROKE, 2010, 41 (10) :2259-2264
[2]   Generalized efficacy of t-PA for acute stroke - Subgroup analysis of the NINDS t-PA stroke trial [J].
Brott, T ;
Broderick, J ;
Kothari, R ;
ODonoghue, M ;
Barsan, W ;
Tomsick, T ;
Spilker, J ;
Miller, R ;
Sauerbeck, L ;
Farrell, J ;
Kelly, J ;
Perkins, T ;
Miller, R ;
McDonald, T ;
Rorick, M ;
Hickey, C ;
Armitage, J ;
Perry, C ;
Thalinger, K ;
Rhude, R ;
Schill, J ;
Becker, PS ;
Heath, RS ;
Adams, D ;
Reed, R ;
Klei, M ;
Hughes, A ;
Anthony, J ;
Baudendistel, D ;
Zadicoff, C ;
Rymer, M ;
Bettinger, I ;
Laubinger, P ;
Schmerler, M ;
Meiros, G ;
Lyden, P ;
Dunford, J ;
Zivin, J ;
Rapp, K ;
Babcock, T ;
Daum, P ;
Persona, D ;
Brody, M ;
Jackson, C ;
Lewis, S ;
Liss, J ;
Mahdavi, Z ;
Rothrock, J ;
Tom, T ;
Zweifler, R .
STROKE, 1997, 28 (11) :2119-2125
[3]   No Increased Risk of Symptomatic Intracerebral Hemorrhage After Thrombolysis in Patients With European Cooperative Acute Stroke Study (ECASS) Exclusion Criteria [J].
Cronin, Carolyn A. ;
Shah, Nikeith ;
Morovati, Tanya ;
Hermann, Lisa D. ;
Sheth, Kevin N. .
STROKE, 2012, 43 (06) :1684-1686
[4]   Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator A Science Advisory From the American Heart Association/American Stroke Association [J].
del Zoppo, Gregory J. ;
Saver, Jeffrey L. ;
Jauch, Edward C. ;
Adams, Harold P., Jr. .
STROKE, 2009, 40 (08) :2945-2948
[5]   Characteristics, Performance Measures, and In-Hospital Outcomes of the First One Million Stroke and Transient Ischemic Attack Admissions in Get With The Guidelines-Stroke [J].
Fonarow, Gregg C. ;
Reeves, Mathew J. ;
Smith, Eric E. ;
Saver, Jeffrey L. ;
Zhao, Xin ;
Olson, Dai Wai ;
Hernandez, Adrian F. ;
Peterson, Eric D. ;
Schwamm, Lee H. .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2010, 3 (03) :291-U122
[6]   Intravenous Alteplase for Stroke in Those Older Than 80 Years Old [J].
Ford, Gary A. ;
Ahmed, Niaz ;
Azevedo, Elsa ;
Grond, Martin ;
Larrue, Vincent ;
Lindsberg, Perttu J. ;
Toni, Danilo ;
Wahlgren, Nils .
STROKE, 2010, 41 (11) :2568-2574
[7]   Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke [J].
Hacke, Werner ;
Kaste, Markku ;
Bluhmki, Erich ;
Brozman, Miroslav ;
Davalos, Antoni ;
Guidetti, Donata ;
Larrue, Vincent ;
Lees, Kennedy R. ;
Medeghri, Zakaria ;
Machnig, Thomas ;
Schneider, Dietmar ;
von Kummer, Ruediger ;
Wahlgren, Nils ;
Toni, Danilo .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (13) :1317-1329
[8]  
Kumar N, 2010, DIABETES CARE, V33, P2531, DOI [10.2337/dc10-1125, 10.2337/dc10.1125]
[9]   TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE [J].
MARLER, JR ;
BROTT, T ;
BRODERICK, J ;
KOTHARI, R ;
ODONOGHUE, M ;
BARSAN, W ;
TOMSICK, T ;
SPILKER, J ;
MILLER, R ;
SAUERBECK, L ;
JARRELL, J ;
KELLY, J ;
PERKINS, T ;
MCDONALD, T ;
RORICK, M ;
HICKEY, C ;
ARMITAGE, J ;
PERRY, C ;
THALINGER, K ;
RHUDE, R ;
SCHILL, J ;
BECKER, PS ;
HEATH, RS ;
ADAMS, D ;
REED, R ;
KLEI, M ;
HUGHES, S ;
ANTHONY, J ;
BAUDENDISTEL, D ;
ZADICOFF, C ;
RYMER, M ;
BETTINGER, I ;
LAUBINGER, P ;
SCHMERLER, M ;
MEIROSE, G ;
LYDEN, P ;
RAPP, K ;
BABCOCK, T ;
DAUM, P ;
PERSONA, D ;
BRODY, M ;
JACKSON, C ;
LEWIS, S ;
LISS, J ;
MAHDAVI, Z ;
ROTHROCK, J ;
TOM, T ;
ZWEIFLER, R ;
DUNFORD, J ;
ZIVIN, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) :1581-1587
[10]   Off-Label Thrombolysis Is Not Associated With Poor Outcome in Patients With Stroke [J].
Meretoja, Atte ;
Putaala, Jukka ;
Tatlisumak, Turgut ;
Atula, Sari ;
Artto, Ville ;
Curtze, Sami ;
Happola, Olli ;
Lindsberg, Perttu J. ;
Mustanoja, Satu ;
Piironen, Katja ;
Pitkaniemi, Janne ;
Rantanen, Kirsi ;
Sairanen, Tiina ;
Salonen, Oili ;
Silvennoinen, Heli ;
Soinne, Lauri ;
Strbian, Daniel ;
Tiainen, Marjaana ;
Kaste, Markku .
STROKE, 2010, 41 (07) :1450-1458